Why Fusion biopsy
The Importance of Fusion Biopsy in Early Cancer Diagnosis:
Prostate cancer can be difficult to detect with traditional methods. The digital rectal exam is limited as a screening tool, and while prostate-specific antigen (PSA) blood test has been used since the 1990s, elevated PSA levels are not always conclusive.
Random ultrasound-guided biopsies often require 12-14 needle samples taken from different areas of the prostrate. Although ultrasound helps guide needle placement, the images do not clearly distinguish cancerous from normal tissue. MRI scans, by contrast, provide higher resolution and reveal more detail in soft tissue such as the prostate gland. While MRI alone cannot diagnose prostate cancer, it can highlight suspicious areas that warrant targeted sampling
Biopsy Facts
• Systematic TRUS biopsies show low cancer detection rates.
• TRUS random biopsy (12 cores): ~33% detection rate.
• TRUS saturation biopsy (30 cores): ~40% detection rate.
BiopSee® Solution
By combining ultrasound with MRI through image fusion and navigated biopsy, BiopSee® supports targeted sampling of image-identified areas:
Published clinical studies have reported the following detection rates for MRI-targeted prostate biopsy techniques performed using BiopSee®
• General detection rate: 58%-70%
• Targeted on mpMRI-suspicious locations detection rate: 86%-100%3
-----
3 Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, et al. A Novel Stereotactic Prostate Biopsy System Integrating Pre-Interventional Magnetic Resonance Imaging and Live Ultrasound Fusion. Journal of Urology [Internet]. 2011 Dec 1 [cited 2025 Dec 8];186(6):2214–20. Available from: https://doi.org/10.1016/j.juro.2011.07.102